证券代码：002688 证券简称：金河生物 公告编号：2025-078 金河生物科技股份有限公司 关于对外投资设立全资子公司的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 一、对外投资概述 金河生物科技股份有限公司（以下简称"公司"）2025 年 8 月 18 日召开第 六届董事会第二十九次会议，以 9 票同意，0 票反对，0 票弃权审议通过了《关 于对外投资设立全资子公司的议案》，同意公司以自有资金投资 1,000 万元于上 海市设立全资子公司金河艾宠易（上海）生物技术有限公司。（最终以工商登记 机关核准登记名称为准）。 根据《公司章程》和《深圳证券交易所股票上市规则》等相关规定，上述对 外投资事项无需提交公司股东大会审议。本次投资不构成关联交易，亦不构成《上 市公司重大资产重组管理办法》规定的重大资产重组。 二、拟成立全资子公司的基本情况 1、公司名称：金河艾宠易（上海）生物技术有限公司 2、公司类型：其他有限责任公司 3、注册资本：1,000万元 4、资金来源及出资方式：公司以自有资金货币形式出资，持股比例为100% 5、法定代表人： ...

证券代码：002688 证券简称：金河生物 公告编号：2025-075 金河生物科技股份有限公司 关于控股股东及其一致行动人持股权益变动触及5%整数倍 的权益变动提示性公告 控股股东内蒙古金河控股有限公司及其一致行动人路牡丹、路漫漫、王晓英、 王志军保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次权益变动性质为股份减少，不触及要约收购。内蒙古金河控股有限 公司（以下简称"金河控股"）于 2025 年 8 月 11 日至 2025 年 8 月 19 日通过集 中竞价和大宗交易方式减持股份数量 15,504,500 股。减持后，金河控股及一致 行动人合计持有公司 263,239,552 股，占公司总股本比例的 35.0000%（占比指 占剔除公司回购专用账户中的股份数量后的总股本的比例），触及 5%的整数倍。 2、本次权益变动不会导致公司控股股东、实际控制人发生变化，不会对公 司经营及治理结构产生影响。 金河生物科技股份有限公司（以下简称"公司"）于 2025 年 8 月 19 日收到 金河 ...

金河生物科技股份有限公司 简式权益变动报告书 上市公司名称：金河生物科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：金河生物 股票代码：002688 信息披露义务人：内蒙古金河控股有限公司 通讯地址：内蒙古自治区呼和浩特市托克托县新坪路81号 信息披露义务人之一致行动人：路牡丹 通讯地址：北京市朝阳区 信息披露义务人之一致行动人：路漫漫 通讯地址：北京市朝阳区 信息披露义务人之一致行动人：王志军 通讯地址：内蒙古呼和浩特市 信息披露义务人之一致行动人：王晓英 通讯地址：内蒙古呼和浩特市 权益变动类型：股份数量减少，持股比例减少 签署日期：2025年8月19日 1 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办 法》《公开发行证券的公司信息披露内容与格式准则第 15 号—权益变动报告书》 等相关的法律、法规、部门规章及其他规定性文件的规定编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人公司章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》和《上市公司收购管理办法》的规定， 本报告书已全 ...

证券时报·数据宝统计显示，金河生物今日收盘价为7.50元，上涨0.40%，日换手率为5.93%，成交额为 3.32亿元，全天主力资金净流出3252.62万元，近5日该股累计下跌3.72%，近5日资金合计净流出1.39亿 元。（数据宝） 8月18日金河生物大宗交易一览 | 成交量 | 成交金 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | 额（万 | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | 元） | （元） | | | | | 265.00 | 1780.80 | 6.72 | -10.40 | 机构专用 | 华西证券股份有限公司呼和 浩特乌兰察布西街证券营业 | | | | | | | 部 | | 261.70 | 1758.62 | 6.72 | -10.40 | 机构专用 | 华西证券股份有限公司呼和 浩特乌兰察布西街证券营业 | | | | | | | 部 | | 117.20 | 787.58 | 6.72 | -10.40 | 机构专用 | 红塔证券股份有限公司景洪 勐养路证券营业部 ...

8月18日，金河生物大宗交易成交997.71万股，成交额6704.6万元，占当日总成交额的16.81%，成交价 6.72元，较市场收盘价7.5元折价10.4%。 ...

证券之星消息，8月18日动物保健板块较上一交易日上涨2.2%，申联生物领涨。当日上证指数报收于 3728.03，上涨0.85%。深证成指报收于11835.57，上涨1.73%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688098 | 申联生物 | 12.83 | 20.02% | 13.27万 | 1.69 Z | | 300871 | 回盛生物 | 24.26 | 7.87% | 30.00万 | 7.20亿 | | 838275 | 驱动力 | 10.02 | 6.60% | 4.35万 | 4273.62万 | | 002141 | 贤丰控股 | 3.91 | 4.27% | 1 85.59万 | 3.38亿 | | 839729 | 永顺生物 | 9.95 | 3.65% | 3.11万 | 3066.40万 | | 871970 | 大禹生物 | 9.98 | 3.42% | 2.96万 | 2928.24万 | | 300119 | 瑞普生物 | ...

Core Insights - A new company, Jinhe Aichongyi (Shanghai) Biotechnology Co., Ltd., has been established with a registered capital of 10 million yuan [1] - The company's business scope includes medical research and experimental development, cell technology research and application, and internet information services for pharmaceuticals [1] - Jinhe Aichongyi is wholly owned by Jinhe Biology (002688) [1]

Core Insights - The animal health sector experienced a significant increase of 3.86% on August 15, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3696.77, up 0.83%, while the Shenzhen Component Index closed at 11634.67, up 1.6% [1] Stock Performance - Shenlian Biological (688088) saw a closing price of 10.69, with a remarkable increase of 19.98% and a trading volume of 435,300 shares, amounting to a transaction value of 441 million yuan [1] - Other notable performers included: - Biological Shares (600201) with a closing price of 8.93, up 6.06% [1] - Ruipu Biological (300119) with a closing price of 22.78, up 5.56% [1] - KQ Biological (688526) with a closing price of 17.24, up 2.44% [1] Capital Flow - The animal health sector saw a net inflow of 49.48 million yuan from institutional investors, while retail investors contributed a net inflow of 40.08 million yuan [1] - Notably, retail funds experienced a net outflow of 89.56 million yuan [1] Detailed Capital Flow Analysis - Shenlian Biological had a net inflow of 54.78 million yuan from institutional investors, while it faced a net outflow of 41.10 million yuan from speculative funds [2] - Biological Shares had a net inflow of 14.26 million yuan from institutional investors, with a net outflow of 33.08 million yuan from speculative funds [2] - Ruipu Biological recorded a net inflow of 1.78 million yuan from institutional investors, while speculative funds saw a net outflow of 16.93 million yuan [2]

Group 1: Industry Overview - The pet economy in China is experiencing significant growth, with domestic pet consumption reaching 77.375 billion yuan in the first half of the year, a year-on-year increase of 8.84% [1] - The average revenue per pet store in mainland China was approximately 137,500 yuan in the first half of the year [1] - The pet industry is evolving from a focus on food and supplies to a comprehensive ecosystem that includes medical care, grooming, training, and insurance [1] Group 2: Market Demand and Company Performance - Zhongchong Co., Ltd. reported total revenue of 2.432 billion yuan in the first half of the year, a year-on-year increase of 24.32%, with a net profit of 203 million yuan, up 42.56% [2] - Tianyuan Pet achieved total revenue of 569 million yuan in the first quarter, a year-on-year increase of 13.07%, with a net profit of 17 million yuan, up 18.97% [2] - Yiyi Co., Ltd. reported total revenue of 485 million yuan in the first quarter, a year-on-year increase of 26.56%, with a net profit of 54 million yuan, up 27.96% [2] Group 3: Future Market Projections - The urban pet consumption market in China is expected to exceed 300 billion yuan by 2024, with the total number of dogs and cats reaching over 120 million [2] - The pet economy is projected to grow to 1.15 trillion yuan by 2028 [2] Group 4: Policy Support and Consumer Trends - Government policies are supporting the growth of the pet economy, with action plans released in Hefei and Foshan to promote high-quality development [3] - The evolving consumer mindset and increasing demand for pet health management and personalized services are driving the growth of the pet economy [3] Group 5: Technological Integration - AI technology is becoming a key driver in the pet economy, with companies integrating AI into pet services and products [4] - New AI-enabled products, such as the "AI Pet Partner" app and smart pet devices, are being developed to enhance pet care [4] Group 6: Digital Transformation in Supply Chain - Companies are focusing on digital transformation to address challenges in order management and inventory coordination [5][6] - The integration of AI and digital platforms is expected to improve operational efficiency and standardization across the pet industry [6] Group 7: Competitive Landscape - The competition in the pet economy is shifting towards technology depth and data barriers, with companies competing on algorithm accuracy and user engagement [6] - New business models may emerge, including AI-based pet health management subscription services and AI-driven customized pet products [6]

Investment Rating - The report does not explicitly state an investment rating for the animal health industry, but it highlights potential growth areas such as pet pharmaceuticals and international expansion [1]. Core Insights - The animal health industry is experiencing a slowdown in growth, with increasing competition leading to a "Matthew Effect" where larger companies gain more market share at the expense of smaller firms [3][39]. - The industry is shifting back to a research and development-driven model, with innovation becoming crucial for future growth [4][83]. - The pet pharmaceutical market and international expansion are identified as key areas for long-term growth, with pet medical consumption projected to reach approximately 84 billion yuan in 2024 [5][78]. Summary by Sections 1. Overview of the Animal Health Industry - The animal health industry, also known as the veterinary drug industry, includes a wide range of products such as vaccines, antibiotics, and feed additives [11][12]. - The market size has grown from 50.395 billion yuan in 2019 to 69.651 billion yuan in 2023, with a CAGR of 8.43% [3][12]. 2. Increasing Competition and Market Dynamics - The industry is facing a slowdown in growth, with sales increasing from 62.095 billion yuan in 2020 to 69.651 billion yuan in 2023, while average gross profit has decreased from 21.998 billion yuan to 21.297 billion yuan [3][39]. - The "Matthew Effect" is evident as larger companies leverage their product portfolios and R&D investments to capture more market share [3][52]. 3. Shift Towards R&D and Innovation - The industry is moving away from its cyclical nature, with a focus on integrated strategies and innovation to counteract competitive pressures [4][69]. - The average profit per head in self-breeding pig farming is expected to improve significantly in 2024, indicating potential for recovery in related sectors [4][62]. 4. Growth Opportunities in Pet Pharmaceuticals and Exports - The pet medical market is projected to grow rapidly, with a significant increase in demand for preventive care and treatment as pet owners become more health-conscious [5][78]. - The report highlights the successful export of domestic pet pharmaceuticals, marking a breakthrough in international markets [5][78]. 5. Key Companies to Watch - Companies such as 瑞普生物 (Reap Bio), 科前生物 (KQ Bio), and 回盛生物 (Hui Sheng Bio) are recommended for attention due to their innovative approaches and market positioning [6].